Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men

HIV Infections Clinical Trial

— RAL-NPEP  

Official title:

Safety, Tolerability, and Adherence to a Raltegravir-based Antiretroviral Regimen for HIV Non-occupational Postexposure Prophylaxis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01087840
• Other study ID #: RAL-NPEP version 1.
• Status: Completed
• Phase: Phase 4
• First received: March 15, 2010
• Last updated: April 15, 2014
• Start date: July 2010
• Est. completion date: July 2012

Study information

• Verified date: April 2014
• Source: St Vincent's Hospital, Sydney
• Contact: n/a
• Is FDA regulated: No
• Health authority: Australia: St. Vincent's Hospital Human Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The use of anti-HIV drugs following a potential sexual or injecting drug use exposure to HIV in order to try and prevent an exposure from becoming an infection is common. This is called nonoccupational postexposure prophylaxis (NPEP). The likelihood of NPEP succeeding is related to intrinsic qualities of the drugs used which includes at which point in the life cycle of the HIV virus the drugs work, how strong the drugs are against HIV, and how well tolerated the drugs are i.e. what side effects they produce. Many people skip doses during their treatment or abandon their treatment because of side effects. The anti-HIV drug raltegravir works early in the life cycle of the virus i.e. before it integrates with human DNA, is potent against HIV and causes few side effects. These qualities make it an obvious choice for use as a NPEP treatment. In this study 100 HIV negative men will receive raltegravir along with another HIV drug called truvada (commonly used in NPEP) for 28 days after a possible sexual exposure to HIV. They will be monitored closely for adverse events, side effects and for their ability to take the medicine each day for the whole 28 days. The hypothesis in this study states that raltegravir use in NPEP will be safe, well tolerated and result in a high treatment completion rate.

Description:

This is a single site, 72-week, prospective, open-label, non-randomized trial. One hundred and 50 (150) eligible participants will be assigned to receive RAL 400 mg BID along with tenofovir disoproxil fumarate/emtricitabine (TVD) 1 tablet once daily (3-drug NPEP) for 28-days or TVD 1 tablet once daily (2-drug NPEP) for 28-days according to established Australian guidelines for the use of 3 or 2-drug NPEP following a potential or actual sexual exposure to HIV in men who have sex with men (MSM).1 Based on hospital NPEP data over the past 2 years, it is anticipated that 100 MSM will receive 3-drug (RAL-TVD) NPEP and 50 will receive 2-drug (TVD) NPEP. Follow-up post NPEP is for 23 weeks i.e. to week 24 post exposure.

Primary study objectives:

To describe the safety of 28 days of nonoccupational post-exposure prophylaxis(NPEP) containing raltegravir (RAL) To describe the tolerability of 28 days of NPEP containing RAL To describe on-drug adherence and regimen completion rates of 28 days of NPEP containing RAL

Secondary study objectives:

To investigate whether or not receipt of NPEP decreases, increases or has no impact on HIV risk taking behaviour To describe the effects of RAL and tenofovir disoproxil fumarate/emtricitabine (TVD) on key inflammatory biomarkers in a subset of the main study population

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: July 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Eligible MSM who, according to Australian NPEP guidelines, or in the opinion of the investigators, are assessed as eligible for NPEP following a potential or actual sexual exposure to HIV who present to St. Vincent's Hospital, Sydney.

Exclusion Criteria:

• Non sexual exposures

• Exposures occurring during sex between a man and a woman

• HIV infection diagnosed on baseline serological testing including indeterminate serology consistent with possible primary HIV infection

• Use of any medication contraindicated with RAL or TVD

• Serum hepatic transaminases (ALT/AST) greater than 5 times the upper limit of normal

• Serum creatinine greater than 2 times the upper limit of normal#

• Therapy with adefovir, tenofovir, emtricitabine, lamivudine, or entecavir for hepatitis B

• Baseline serological evidence of chronic/active hepatitis B

• Previous NPEP containing RAL in the study period

• A patient with a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections
• HIV Prevention

Intervention

Drug:
• Raltegravir
Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days. Arms: Raltegravir/Truvada Other Names: Isentress/Truvada

Locations

Country	Name	City	State
Australia	St. Vincent's Hospital, 390 Victoria Rd, Darlinghurst	Sydney	New South Wales
Australia	Sydney Sexual Health, Sydney Hospital	Sydney	New South Wales

Sponsors (2)

Lead Sponsor	Collaborator
Andrew Carr	Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To describe the safety of 28 days of nonoccupational post-exposure prophylaxis containing raltegravir	Objective AE and SAE data collection/grading utilising DAIDS data collection tool. Measurement of weight and vital signs, electrolytes, urea, creatinine, eGFR, inorganic phosphate, calcium, liver function, glucose, amylase, lipase, creatine kinase, lactate, urinalysis	28 days on drug with 5 month follow-up	Yes
Primary	To describe the tolerability of 28 days of NPEP containing raltegravir	Subjective reporting of AEs with data collection/grading utilising DAIDS-AE	28 days on-drug and 5 months follow-up	Yes
Primary	To describe on-drug adherence and regimen completion rates of 28 days of NPEP containing raltegravir	Adherence measurement by self report and pill count at 3 time points during the 28-days of NPEP	28 days	No
Secondary	To describe the context of the risk	Context of risk event described using directed questioning around pre determined variables	Baseline visit day 1 of NPEP	No
Secondary	To investigate whether or not receipt of NPEP decreases, increases or has no impact on future HIV risk taking behaviour	Baseline data collection of HIV risk behaviour in 6 months preceeding NPEP. Repeat data collection at week 12 and week 24 post NPEP risk event. Data collected utilising assisted completion of HIV related behaviour questionaire.	Visit 2 (day 3-5 of study), visit 7 (day 82-84 of study) visit 9 (day 166-168 of study)	No
Secondary	To describe the effects of raltegravir and truvada on key inflammatory biomarkers	Measurement of CR-P, D-Dimer, IL-6 on a subset of 50 patients receiving raltegravir/truvada NPEP and a subset of 25 patients receiving truvada alone as NPEP.	Day 1 and day 28 of NPEP	No